Table 1. Summary of murine vaccination experiments comparing immunogenicity of PLGA/PLA particles encapsulating Ag (+/−adjuvant).
Compared sizes | Polymer | Vaccination route | Cargo | Results summary | References | |
---|---|---|---|---|---|---|
Output | Optimum size(s) | |||||
500 nm, 2 μm, and 7 μm | PLGA 50:50 | IP | OVA | Th1 + CTL responses | 500 nm | 41 |
300 nm, 1 μm, 7 μm, and 17 μm | PLGA 50:50 | IP | OVA and CpG | IgG2a + CTL responses | 300 nm | 35 |
200 nm, 500 nm, and 1 μm | PLGA 50:50 | subQ or Oral | BSA | IgG responses | 1 μm | 43 |
200–600 nm vs 2–8 μm | PLA | IM | HBsAg | Th1 responses | 200–600 nm | 44 |
Th2 responses | 2–8 μm | |||||
50–150 μm, 10–70 μm, 2–8 μm and < 2 μm | PLA | IM | Tetanus Toxoid | IgG responses | 2–8 μm | 45 |
1 μm and 5 μm | PLGA 50:50 | Oral | BSA | IgG responses | 1 μm | 46 |
IP, intraperitoneal; subQ, subcutaneous; IM, intramuscular; HBsAg, hepatitis B surface antigen; CTL, cytotoxic T lymphocyte.